Perspectives on cancer stem cells in osteosarcoma

Cancer Letters

Volumn 338, Issue 1, 2013, Pages 158-167

  Basu Roy, Upal ^a   Basilico, Claudio ^a   Mansukhani, Alka ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone cancer; Cancer stem cell; FGF; Mesenchymal tumors; Osteosarcoma; Sox2; Tumor initiating cell; Wnt signaling

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CELL SURFACE MARKER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; STEM CELL ANTIGEN 1; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

BONE MARROW CELL; CANCER GENETICS; CANCER STEM CELL; CARCINOGENESIS; CELL ASSAY; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL SUBPOPULATION; CHROMOSOME ANALYSIS; CLONAL EVOLUTION; DRUG TARGETING; DYE EXCLUSION; DYE RETENTION; ENZYME ACTIVITY; ENZYME ASSAY; EPIGENETICS; FUNCTIONAL CHARACTERIZATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; LIMITING DILUTION ASSAY; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; MULTIPOTENCY ASSAY; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; SHORT SURVEY; STAINING; TUMOR GROWTH; TUMOR INITIATING CELL; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

EID: 84882904822     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.028     Document Type: Review

References (106)

1. Cormier J.N., Pollock R.E. Soft tissue sarcomas. CA Cancer J. Clin. 2004, 54:94-109.
2. Heare T., Hensley M.A., Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr. Opin. Pediatr. 2009, 21:365-372.
3. Hansen M.F., Seton M., Merchant A. Osteosarcoma in Paget's disease of bone. J. Bone Miner. Res. 2006, 21(2):P58-P63.
4. Ottaviani G., Jaffe N. The epidemiology of osteosarcoma. Cancer Treat. Res. 2009, 152:3-13.
5. Caudill J.S., Arndt C.A. Diagnosis and management of bone malignancy in adolescence. Adolesc. Med. State Art. Rev. 2007, 18:62-78. ix.
6. Marina N., Gebhardt M., Teot L., Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422-441.
7. Meyers P.A., Heller G., Healey J., Huvos A., Lane J., Marcove R., Applewhite A., Vlamis V., Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J. Clin. Oncol. 1992, 10:5-15.
8. Meyers P.A., Schwartz C.L., Krailo M., Kleinerman E.S., Betcher D., Bernstein M.L., Conrad E., Ferguson W., Gebhardt M., Goorin A.M., Harris M.B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R., Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 2005, 23:2004-2011.
9. PosthumaDeBoer J., Witlox M.A., Kaspers G.J., van Royen B.J. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin. Exp. Metastasis 2011, 28:493-503.
10. Bridge J.A., Nelson M., McComb E., McGuire M.H., Rosenthal H., Vergara G., Maale G.E., Spanier S., Neff J.R. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet. Cytogenet. 1997, 95:74-87.
11. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet. Cytogenet. 2003, 145:1-30.
12. Smida J., Baumhoer D., Rosemann M., Walch A., Bielack S., Poremba C., Remberger K., Korsching E., Scheurlen W., Dierkes C., Burdach S., Jundt G., Atkinson M.J., Nathrath M. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin. Cancer Res. 2010, 16:4256-4267.
13. Tang N., Song W.X., Luo J., Haydon R.C., He T.C. Osteosarcoma development and stem cell differentiation. Clin. Orthop. Relat. Res. 2008, 466:2114-2130.
14. Helman L.J., Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 2003, 3:685-694.
15. Janeway K.A., Walkley C.R. Modeling human osteosarcoma in the mouse: from bedside to bench. Bone 2010, 47:859-865.
16. Jones K.B. Osteosarcomagenesis: modeling cancer initiation in the mouse. Sarcoma 2011, 2011:694136.
17. Berman S.D., Calo E., Landman A.S., Danielian P.S., Miller E.S., West J.C., Fonhoue B.D., Caron A., Bronson R., Bouxsein M.L., Mukherjee S., Lees J.A. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc. Natl. Acad. Sci. USA 2008, 105:11851-11856.
18. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., Roth S.I., Rodda S.J., Snay E., Dunning P., Fahey F.H., Alt F.W., McMahon A.P., Orkin S.H. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008, 22:1662-1676.
19. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., Okita K., Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
20. Marion R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., Fernandez-Capetillo O., Serrano M., Blasco M.A. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
21. Rosemann M., Kuosaite V., Nathrath M., Atkinson M.J. The genetics of radiation-induced and sporadic osteosarcoma: a unifying theory?. J. Radiol. Prot. 2002, 22:A113-116.
22. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
23. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
24. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
25. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
26. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
27. Gibbs C.P., Kukekov V.G., Reith J.D., Tchigrinova O., Suslov O.N., Scott E.W., Ghivizzani S.C., Ignatova T.N., Steindler D.A. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005, 7:967-976.
28. Fujii H., Honoki K., Tsujiuchi T., Kido A., Yoshitani K., Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int. J. Oncol. 2009, 34:1381-1386.
29. Adhikari A.S., Agarwal N., Wood B.M., Porretta C., Ruiz B., Pochampally R.R., Iwakuma T. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010, 70:4602-4612.
30. Tirino V., Desiderio V., d'Aquino R., De Francesco F., Pirozzi G., Graziano A., Galderisi U., Cavaliere C., De Rosa A., Papaccio G., Giordano A. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PloS One 2008, 3:e3469.
31. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., Fazioli F., Pirozzi G., Papaccio G. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J.: Off. Publ. Feder. Am. Soc. Exp. Biol. 2011, 25:2022-2030.
32. Basu-Roy U., Seo E., Ramanathapuram L., Rapp T.B., Perry J.A., Orkin S.H., Mansukhani A., Basilico C. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2011, 31:2270-2282.
33. Rainusso N., Man T.K., Lau C.C., Hicks J., Shen J.J., Yu A., Wang L.L., Rosen J.M. Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model. Cancer Biol. Ther. 2011, 12:278-287.
34. Murase M., Kano M., Tsukahara T., Takahashi A., Torigoe T., Kawaguchi S., Kimura S., Wada T., Uchihashi Y., Kondo T., Yamashita T., Sato N. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Brit. J. Cancer 2009, 101:1425-1432.
35. Yang M., Yan M., Zhang R., Li J., Luo Z. Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells. Cancer Sci. 2011, 102:1774-1781.
36. Honoki K., Fujii H., Kubo A., Kido A., Mori T., Tanaka Y., Tsujiuchi T. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol. Rep. 2010, 24:501-505.
37. Wang L., Park P., Zhang H., La Marca F., Lin C.Y. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int. J. Cancer 2011, 128:294-303.
38. Siclari V.A., Qin L. Targeting the osteosarcoma cancer stem cell. J. Orthop. Surg. Res. 2010, 5:78.
39. Morikawa S., Mabuchi Y., Kubota Y., Nagai Y., Niibe K., Hiratsu E., Suzuki S., Miyauchi-Hara C., Nagoshi N., Sunabori T., Shimmura S., Miyawaki A., Nakagawa T., Suda T., Okano H., Matsuzaki Y. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med. 2009, 206:2483-2496.
40. Pevsner-Fischer M., Levin S., Zipori D. The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev. 2011, 7:560-568.
41. Kelly S.E., Di Benedetto A., Greco A., Howard C.M., Sollars V.E., Primerano D.A., Valluri J.V., Claudio P.P. Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications. PloS One 2010, 5:e10035.
42. Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010, 327:542-545.
43. Takeda N., Jain R., LeBoeuf M.R., Wang Q., Lu M.M., Epstein J.A. Interconversion between intestinal stem cell populations in distinct niches. Science 2011, 334:1420-1424.
44. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8:97-106.
45. Blanpain C., Mohrin M., Sotiropoulou P.A., Passegue E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 2011, 8:16-29.
46. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011, 7:292-306.
47. Gangemi R., Paleari L., Orengo A.M., Cesario A., Chessa L., Ferrini S., Russo P. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr. Med. Chem. 2009, 16:1688-1703.
48. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143.
49. Rosen J.M., Jordan C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324:1670-1673.
50. O'Brien C.A., Kreso A., Jamieson C.H. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16:3113-3120.
51. Reynolds B.A., Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255:1707-1710.
52. Pastrana E., Silva-Vargas V., Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011, 8:486-498.
53. Hill R.P., Perris R. "Destemming" cancer stem cells. J. Natl. Cancer Inst. 2007, 99:1435-1440.
54. L. Wang, P. Park, C.Y. Lin, Characterization of stem cell attributes in human osteosarcoma cell lines, Cancer Biol. Ther. 8 (2009).
55. Wilson H., Huelsmeyer M., Chun R., Young K.M., Friedrichs K., Argyle D.J. Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet. J. 2008, 175:69-75.
56. Levings P.P., McGarry S.V., Currie T.P., Nickerson D.M., McClellan S., Ghivizzani S.C., Steindler D.A., Gibbs C.P. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 2009, 69:5648-5655.
57. Gibbs C.P., Levings P.P., Ghivizzani S.C. Evidence for the osteosarcoma stem cell. Curr. Orthop. Pract. 2011, 22:322-326.
58. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
59. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
60. Ducy P., Schinke T., Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000, 289:1501-1504.
61. Lian J.B., Stein G.S., Javed A., van Wijnen A.J., Stein J.L., Montecino M., Hassan M.Q., Gaur T., Lengner C.J., Young D.W. Networks and hubs for the transcriptional control of osteoblastogenesis. Rev. Endocr. Metab. Disord. 2006, 7:1-16.
62. Olsen B.R., Reginato A.M., Wang W. Bone development. Annu. Rev. Cell Dev. Biol. 2000, 16:191-220.
63. Thomas D.M., Carty S.A., Piscopo D.M., Lee J.S., Wang W.F., Forrester W.C., Hinds P.W. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol. Cell 2001, 8:303-316.
64. Calo E., Quintero-Estades J.A., Danielian P.S., Nedelcu S., Berman S.D., Lees J.A. Rb regulates fate choice and lineage commitment in vivo. Nature 2010, 466:1110-1114.
65. Berman S.D., Yuan T.L., Miller E.S., Lee E.Y., Caron A., Lees J.A. The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development. Mol. Cancer Res. 2008, 6:1440-1451.
66. Gutierrez G.M., Kong E., Sabbagh Y., Brown N.E., Lee J.S., Demay M.B., Thomas D.M., Hinds P.W. Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. Proc. Natl. Acad. Sci. USA 2008, 105:18402-18407.
67. Lengner C.J., Steinman H.A., Gagnon J., Smith T.W., Henderson J.E., Kream B.E., Stein G.S., Lian J.B., Jones S.N. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J. Cell Biol. 2006, 172:909-921.
68. Wang X., Kua H.Y., Hu Y., Guo K., Zeng Q., Wu Q., Ng H.H., Karsenty G., de Crombrugghe B., Yeh J., Li B. P53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J. Cell Biol. 2006, 172:115-125.
69. Thomas D.M., Johnson S.A., Sims N.A., Trivett M.K., Slavin J.L., Rubin B.P., Waring P., McArthur G.A., Walkley C.R., Holloway A.J., Diyagama D., Grim J.E., Clurman B.E., Bowtell D.D., Lee J.S., Gutierrez G.M., Piscopo D.M., Carty S.A., Hinds P.W. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J. Cell Biol. 2004, 167:925-934.
70. Williams S.A., Maecker H.L., French D.M., Liu J., Gregg A., Silverstein L.B., Cao T.C., Carano R.A., Dixit V.M. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 2011, 146:918-930.
71. Wagner E.R., Luther G., Zhu G., Luo Q., Shi Q., Kim S.H., Gao J.L., Huang E., Gao Y., Yang K., Wang L., Teven C., Luo X., Liu X., Li M., Hu N., Su Y., Bi Y., He B.C., Tang N., Luo J., Chen L., Zuo G., Rames R., Haydon R.C., Luu H.H., He T.C. Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma 2011, 2011:325238.
72. Mohseny A.B., Szuhai K., Romeo S., Buddingh E.P., Briaire-de Bruijn I., de Jong D., van Pel M., Cleton-Jansen A.M., Hogendoorn P.C. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J. Pathol. 2009, 219:294-305.
73. Koide Y., Morikawa S., Mabuchi Y., Muguruma Y., Hiratsu E., Hasegawa K., Kobayashi M., Ando K., Kinjo K., Okano H., Matsuzaki Y. Two distinct stem cell lineages in murine bone marrow. Stem Cells 2007, 25:1213-1221.
74. Bian Z.Y., Fan Q.M., Li G., Xu W.T., Tang T.T. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. 2010, 101:2554-2560.
75. Brune J.C., Tormin A., Johansson M.C., Rissler P., Brosjo O., Lofvenberg R., von Steyern F.V., Mertens F., Rydholm A., Scheding S. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Int. J. Cancer 2011, 129:319-330.
76. Long M.W., Robinson J.A., Ashcraft E.A., Mann K.G. Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J. Clin. Invest. 1995, 95:881-887.
77. Tare R.S., Babister J.C., Kanczler J., Oreffo R.O. Skeletal stem cells: phenotype, biology and environmental niches informing tissue regeneration. Mol. Cell Endocrinol. 2008, 288:11-21.
78. Wang L., Park P., Zhang H., La Marca F., Claeson A., Valdivia J., Lin C.Y. BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol. Ther. 2011, 11:457-463.
79. Dvorak P., Dvorakova D., Hampl A. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett. 2006, 580:2869-2874.
80. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
81. Marie P.J., Coffin J.D., Hurley M.M. FGF and FGFR signaling in chondrodysplasias and craniosynostosis. J. Cell Biochem. 2005, 96:888-896.
82. Mansukhani A., Bellosta P., Sahni M., Basilico C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol. 2000, 149:1297-1308.
83. Mansukhani A., Ambrosetti D., Holmes G., Cornivelli L., Basilico C. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J. Cell Biol. 2005, 168:1065-1076.
84. Dailey L., Ambrosetti D., Mansukhani A., Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005, 16:233-247.
85. Go M.J., Takenaka C., Ohgushi H. Effect of forced expression of basic fibroblast growth factor in human bone marrow-derived mesenchymal stromal cells. J. Biochem. 2007, 142:741-748.
86. Wiedlocha A., Falnes P.O., Rapak A., Munoz R., Klingenberg O., Olsnes S. Stimulation of proliferation of a human osteosarcoma cell line by exogenous acidic fibroblast growth factor requires both activation of receptor tyrosine kinase and growth factor internalization. Mol. Cell Biol. 1996, 16:270-280.
87. Baird K., Davis S., Antonescu C.R., Harper U.L., Walker R.L., Chen Y., Glatfelter A.A., Duray P.H., Meltzer P.S. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005, 65:9226-9235.
88. T. Shimizu, T. Ishikawa, S. Iwai, A. Ueki, E. Sugihara, N. Onishi, S. Kuninaka, T. Miyamoto, Y. Toyama, H. Ijiri, H. Mori, Y. Matsuzaki, T. Yaguchi, H. Nishio, Y. Kawakami, Y. Ikeda, H. Saya, Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma, Mol. Cancer Res. (2012).
89. Baron R., Rawadi G., Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr. Top Dev. Biol. 2006, 76:103-127.
90. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 2006, 116:1202-1209.
91. Moon R.T., Bowerman B., Boutros M., Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002, 296:1644-1646.
92. Matushansky I., Hernando E., Socci N.D., Mills J.E., Matos T.A., Edgar M.A., Singer S., Maki R.G., Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest. 2007, 117:3248-3257.
93. Matushansky, Maki R.G., Cordon-Cardo C. A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle 2008, 7:720-724.
94. Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrich M., Dobrovic A., Slavin J., Choong P.F., Simmons P.J., Dawid I.B., Thomas D.M. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 2009, 119:837-851.
95. Cai Y., Mohseny A.B., Karperien M., Hogendoorn P.C., Zhou G., Cleton-Jansen A.M. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J. Pathol. 2010, 220:24-33.
96. Cleton-Jansen A.M., Anninga J.K., Briaire-de Bruijn I.H., Romeo S., Oosting J., Egeler R.M., Gelderblom H., Taminiau A.H., Hogendoorn P.C. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br. J. Cancer 2009, 101:1909-1918.
97. Vijayakumar S., Liu G., Rus I.A., Yao S., Chen Y., Akiri G., Grumolato L., Aaronson S.A. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. Cancer Cell 2011, 19:601-612.
98. Bisson I., Prowse D.M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009, 19:683-697.
99. Kanwar S.S., Yu Y., Nautiyal J., Patel B.B., Majumdar A.P. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol. Cancer 2010, 9:212.
100. Paranjape A.N., Mandal T., Mukherjee G., Kumar M.V., Sengupta K., Rangarajan A. Introduction of SV40ER and hTERT into mammospheres generates breast cancer cells with stem cell properties. Oncogene 2012, 31:1896-1909.
101. Yu Y., Kanwar S.S., Patel B.B., Oh P.S., Nautiyal J., Sarkar F.H., Majumdar A.P. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012, 33:68-76.
102. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
103. Tang Q.L., Zhao Z.Q., Li J.C., Liang Y., Yin J.Q., Zou C.Y., Xie X.B., Zeng Y.X., Shen J.N., Kang T., Wang J. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011, 311:113-121.
104. Rainusso N., Brawley V.S., Ghazi A., Hicks M.J., Gottschalk S., Rosen J.M., Ahmed N. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 2012, 19:212-217.
105. Brattain M.G., Fine W.D., Khaled F.M., Thompson J., Brattain D.E. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 1981, 41:1751-1756.
106. Fuerer C., Nusse R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One 2010, 5:e9370.